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Introduction
One-in-seven men will be diagnosed with prostate cancer (PC) in their lifetime and PC related deaths is above twenty thousand per year in the US (1) . PC is driven by androgen receptor (AR) activation, making androgen deprivation therapy (ADT) the mainstay of treatment for men with advanced PC. Despite initial efficacy, patients inevitably relapse despite castrate levels of serum testosterone, a lethal condition known as castrate-resistant prostate cancer (CRPC) (1, 2) .
Targeted therapies to manage PC are limited to AR signaling, although recent clinical trials are assessing the therapeutic efficacy of inhibiting the PI3K/mTORC1 pathway (2) . Overexpression of the MYC oncogene is among the most common alterations in PC, with over 30 percent of localized and a majority of CRPC tumors showing MYC overexpression (3, 4) . MYC controls cell growth by transcriptionally upregulating components involved in ribosome biogenesis, including direct binding to ribosomal RNA (rRNA) genes, which hyper-activates the synthesis of rRNA (5-7).
In PC, MYC expression positively correlates with the overexpression of rRNA (8) . Additionally, the PIM kinases, consisting of three paralogs (PIM1, 2, 3) with pro-oncogenic activities, were shown to be concurrently over-expressed with MYC in PC (9) . PIM kinases increase MYC transcriptional activity (10) and stability (11) , they also stimulate eIF4E-dependent mRNA translation through stimulation of 4E-BP1 phosphorylation at serine 65 (12) . This accelerates prostate tumor growth and mediates resistance to conventional therapies (13) (14) (15) . It has been documented that MYC-driven hematological cancers are sensitive to inhibition of eIF4E-dependent mRNA translation (16) . Therefore, we hypothesized that targeting ribosome biogenesis and function by inhibiting Pol I transcriptional activity alone, or in combination with inhibitors or modulators of mRNA translation (such as PIM kinases) may represent a novel method of treating MYC-driven PC.
Here, we demonstrate the efficacy of a novel small molecule inhibitor of Pol I transcription, CX-5461, in inhibiting growth, colony formation and in inducing cell death in human PC cells. Using a genetically engineered mouse model (GEMM) of PC, the Hi-MYC model (17) , we demonstrate that CX-5461 suppresses tumor progression in vivo. Strikingly, CX-5461 in combination therapy with the pan-PIM kinase inhibitor CX-6258, lead to a reversion of Hi-MYC tumors back to high grade intraepithelial neoplasia (HGPIN). This correlated with repression of ribosome biogenesis (reduced rRNA synthesis) and ribosome function (reduced 4EBP1 phosphorylation).
Furthermore, and as a proof of principle of promising preclinical efficacy, this combination therapy prevented tumor growth in a GEMM of PTEN depletion and a PDX model of aggressive high-MYC PC unresponsive to conventional therapy.
Materials and Methods

Cell culture
Authenticated PC-3, DU145 and LNCaP human prostate cell lines were purchased from the American Type Culture Collection and cultivated in RPMI supplemented with 10% FBS. BM67 mouse prostate epithelial cells were generated from PBiCre +/-;Pten fl/fl mice and validated as outlined previously (18) . The HM-5 mouse prostate cell line was generated from a 5 month old male FVB-Tg(ARR2/Pbsn-MYC) lateral prostate. Briefly, lateral prostate lobes were isolated and minced into 5 mm3 pieces and digested at 37ºC for 2 hours in DMEM medium containing HEPES and 1 mg/ml collagenase (Sigma-Aldrich, USA). Post-digestion, prostate pieces were washed in Phosphate-buffered saline (PBS), then transferred to a 100 mm plasma gas treated tissue culture dish (BD Biosciences, USA). Cells were grown in growth medium containing RPMI supplemented with 10% FBS (Invitrogen, USA), human recombinant epithelial growth factor (life technologies, USA), Bovine Pituitary Extract (life technologies, USA), Insulin (Sigma-Aldrich, USA), Penicillin/Streptomycin (P/S) and 10 nM testosterone (T) (SigmaAldrich, USA) and Y-27632 (Sigma-Aldrich, USA) and the media was replaced every 4 days.
Colonies were isolated then maintained in RPMI containing 5% FBS, P/S and 10 nM T and kept in a humidified incubator at 37ºC with 5% CO2.
Inhibitors
CX-5461 and CX-6258 were generous gifts from Cylene Pharmaceuticals (San Diego, CA).
RAD001 was purchased from Selleck Chemicals (Houston, TX).
Anchorage-independent growth assays
PC3 and DU145 cells were seeded into 6-well plates as single cell suspensions in 0.35% sterile low melt agarose (Bioline, USA) on a 0.7% agarose base layer and incubated overnight as described previously (19) . These plates were then cultured for 3 weeks to allow colony suspensions to form.
Cell cycle analysis
Seeded PC-3 and DU145 cells were serum starved for 24 hours prior to incubation with inhibitors in order to synchronise the cell cycle at G0 phase of the cell cycle. Cells were fixed in 70% ethanol, stained with Propidium Iodide (PI) and analysed 24 hours after incubation with inhibitors on an LSR Fortessa Cell Analyser (BD Biosciences, USA).
Animal experiments
Hi-MYC (ARR2pbsn-MYC) mice were obtained from NCI-Frederick, USA and PTEN-deficient (PBiCre+/-;PTENfl/fl) mice were obtained from a breeding colony established at the Peter MacCallum Cancer Centre, Australia. Transgenic Hi-MYC female mice were crossed with wildtype male mice to generate transgenic Hi-MYC male progeny. PBi-Cre transgenic mice (20) were crossed with PTEN floxed animals (21) to specifically deplete PTEN within the prostate epithelium. Animals were maintained on a pure FVB/N background. Both Hi-MYC and PTEN mice were aged to 4 months and given oral doses of inhibitor, bi-weekly over 4 weeks (9 doses).
For acute experiments, a single dose of inhibitor was administered over 24 hours. All Hi-MYC and PTEN-deficient animals were humanely killed at 5 months of age, 24 hours after the final dose of inhibitor.
Histology & immunohistochemistry (IHC)
Lateral prostate lobes were isolated from animals 24 hours post therapy and fixed in formalin for 48 hours before histological processing. Entire prostate lobes were sectioned at 5 µm thick and 
Western blotting
Protein extracts were isolated by lysis in passive lysis buffer solution (Progen, USA). Whole animal prostate lobe tissues were ground into a powder in liquid nitrogen using a pre-chilled mortar and pestle and protein lysates were prepared by dissolving the powdered tissue in SDS lysis buffer. A detailed description is provided in supplemental methods.
Ribosomal RNA extraction and q-PCR
Isolated prostate lobes were snap frozen and maintained at -80ºC until analysed. Tissue was homogenised by crushing in liquid nitrogen, then cells were lysed and the RNA extracted using then NucleoSpin kit (Macherey-Nagel, Germany). SuperScript III Reverse Transcriptase 
Statistical analysis
Graphpad Prism software was used to generate graphs and perform statistical analyses and significance of data. In vitro experiments were performed in triplicate and expressed as a summary of the mean of replicates with standard deviation (SD), unless specified otherwise.
Histological quantitation of mouse prostate tissue was performed using an Aperio ScanScope digital scanner and viewed using ImageScope software (Aperio).
Animal Ethics
All animal experiments were performed according to protocols approved by the Monash University Animal Ethics Committee, Monash University.
Patient derived xenografts
Human tissues were obtained post-mortem during autopsy. Tissue collection was performed according to approved Human ethics (Peter MacCallum Cancer Centre). Tumor grafts were implanted under the renal capsule of immunodeficient mice (NSG) according to our previously published protocol (24) with the following modifications: tissue was sectioned in thin 0.3 mm slices using a Krumdieck tissue slicer MD6000 (TSE systems, Germany) and grafted under the renal capsule without adding seminal vesicle mesenchymal cells or prostate fibroblasts. Grafts were allowed to establish in testosterone supplemented hosts for a period of 3 weeks prior to treatment. Host mice were treated with vehicle or CX-5461/CX-6258 combination and given 4 doses over 9 days. Mice were humanely killed 24 hours after the last dose and grafts were harvested. Grafted tissues were measured, weighed and fixed in 10% formalin for 24 hours prior to being processed and embedded in paraffin. activity (22) . Both PC3 and DU145 cells are p53 null while LNCaP cells express functional p53 (25) . Accordingly, phosphorylated p53 accumulation was observed in LNCaP cells at 2 hours following treatment with CX-5461 ( Figure 1G ). This p53 accumulation was also accompanied by an increase in p21 at 8 and 24 hours post-treatment ( Figure 1G ). These results show that CX-5461 is cytostatic in PC cell lines, arresting cells in G2M. The lack of apoptosis is not simply due to the lack of p53 as LNCaP also arrest in G2M despite activating a p53 response. These data are consistent with our earlier studies demonstrating that in solid tumors therapeutic efficacy of CX-5461 does not correlate with p53 status (26), but can promote sensitivity when present.
Results
PC cells are sensitive to CX-5461, an inhibitor of RNA
Together, these results demonstrate that PC cells are sensitive to Pol I transcription inhibition in vitro, leading to significant cell cycle arrest that abrogates colony formation.
RNA polymerase I activity inhibition suppresses tumor progression in MYC-driven prostate cancer, in vivo
In order to evaluate CX-5461 potential to prevent disease progression in vivo, we employed a GEMM that faithfully recapitulates human disease progression from PIN to invasive carcinoma.
GEMM of PC have the advantage of developing autochthonous tumors at high penetrance and with reproducible kinetics. To test if the sensitivity of PC cell lines to Pol I transcription inhibition would translate to a therapeutic effect in vivo we tested CX-5461 in the Hi-MYC mouse (17) . The Hi-MYC mouse reproduces the pathological development of human PC. In this model, MYC expression is under the control of the probasin promoter, which is prostate-specific and androgen-dependent. Neoplastic lesions develop initially in the ventral and lateral lobes (17) .
High grade intra-epithelial neoplasia (PIN) is observed at 2 months of age; in situ carcinoma is fully penetrant at 5 months of age. We followed disease progression at various time points (Figure 2A ) and our observations show a reproducible and highly penetrant phenotype. At 5 months of age we observed the development of multiple invasive lesions while, by 8 months, invasive lesions occupied most of the ventral and lateral lobes (Figure 2A ). This is characterized by the loss or fragmentation of the smooth muscle actin layer surrounding the prostatic ducts, as previously reported (17, 27) . Hi-MYC tumors are highly proliferative (17) Five month old Hi-MYC mice (n=3 per group) were treated with CX-5461 at a dose of 50 mg/kg. This dose was previously shown to induce therapeutic effects in a MYC-driven murine model of lymphoma (22) . Following 24 hours of treatment lateral prostate tissue was isolated and analyzed for Pol I transcription rate by measuring the abundance of the 45S pre-ribosomal RNA (rRNA) ( Figure 2C ) and for induction of p53 ( Figure 2D ), which is a known marker of the immediate response to RNA Pol I transcription inhibition in p53 WT tumors in vivo (22) .
Animals treated with CX-5461 for 24 hours displayed a significant reduction (66% ± 26%) in the amount of 45S pre-rRNA ( Figure 2C ) (n=3, P=0.048), which correlated with a robust accumulation of p53 in the same tissues ( Figure 2D ). We then examined the therapeutic effect of a longer term dosage of CX-5461 in Hi-MYC mice. Four-month old Hi-MYC mice were dosed twice weekly for 4 weeks, with 50 mg/kg CX-5461 for a total of 9 doses (n=3 per group). At sacrifice, lateral prostate tissue was harvested and analyzed by IHC. While the number of MYC expressing epithelial cells were not significantly reduced in these tissue sections ( Figure 2E, F 
Co-targeting PIM kinase activity potentiates the effect of RNA polymerase I activity inhibition in prostate cancer cells.
As previously mentioned, PIM-1 is co-elevated with MYC in human and Hi-MYC prostate adenocarcinoma, where it is believed to accelerate tumorigenesis (17) . It was recently shown that resistance to therapy with the mTORC1 inhibitor, RAD001, is mediated by up-regulated signaling via eukaryotic initiation factor 4E binding protein-1 (4E-BP1) in Hi-MYC mice (15, 28) , a PIM kinase substrate (29) . Additionally, a PIM inhibitor has been reported recently to have efficacy in a model of MYC-driven prostate cancer (30) . We therefore examined whether suppressing ribosome biogenesis with CX-5461 and PIM kinase activity co-operate in PC
inhibition. Firstly, we tested the efficacy of CX-6258, a novel pan-PIM inhibitor (31) in inhibiting anchorage-independent growth of PC3 and DU145 cells. CX-6258 significantly suppressed colony formation of PC3 and DU145 cells (n=3, P<0.001) ( Figure 3A Figure 4G ). Viability of HM-5 cells was assessed after 72 hours incubation with CX-5461, CX-6258 or in combination and showed that indeed these drugs cooperate to induce cell death at this concentration ( Figure 4H ). Together, this data demonstrates that combined Pol I transcription inhibition and PIM kinase inhibition co-operates in vitro to enhance efficacy of each inhibitor in Hi-MYC tumor cells.
Co-targeting RNA Pol I and PIM in the Hi-MYC and the PTEN-deficient models of PC
We next examined whether the robust effect of combining Pol I inhibition with PIM inhibition on MYC-driven PC in vitro translated to an improved therapeutic outcome in vivo. To test this, four-month old Hi-MYC mice were treated with single agents or combination therapy for 4 weeks, bi-weekly, and the effect of therapy on lateral prostate adenocarcinoma were analyzed via histopathological assessment and IHC with 8-11 animals per treatment group (Vehicle: n=11, CX-5461: n=8, CX-6258: n=8, combination: n=11). Animals on combination therapy had a markedly improved phenotype, displaying HGPIN as the most prevalent lesion compared with vehicle alone or either inhibitor alone ( Figure 5A ). While assessing the occurrence of invasive lesions in the same groups, we observed that CX-5461 alone drastically reduced the number of invasive lesions ( Figure 5B ). There was no striking difference in the histopathology of lesions in CX-6258 treated animals compared with animals treated with vehicle only, indicating that inhibiting PIM alone may have limited impact in preventing MYC induced adenocarcinoma. Similar to CX-5461 alone, combination therapy suppressed the incidence of invasive foci in almost all treated animals (9/11 animals) ( Figure 5B ). In addition, cell proliferation, as marked by Ki-67, was significantly lower in animals treated with combination therapy as compared with other groups ( Figure 5C ). These results highlight the fact that PIM co-operates with MYC but does not direct MYC oncogenic influence completely.
Importantly, there was no impact on body weight of animals in any of the treatment groups, indicating these drugs were well tolerated in combination ( Figure S2 ) and provide a novel and potent therapeutic approach to treat PC. In contrast with these findings, but in agreement with results reported by Clegg and colleagues (28) , no cooperativity was observed in vivo in Hi-MYC mice when combining CX-5461 with RAD001, a partial inhibitor of mTORC1 ( Figure S3 ).
We then examined whether this robust combination effect could be validated in another GEMM of PC by employing the conditional PTEN-KO model (33, 34) , where MYC expression is comparatively low. Again, four-month old PTEN-deficient mice were treated for 4 weeks, biweekly, and the effect of therapy on anterior prostate carcinoma were analyzed via histopathological assessment with 4 animals per treatment group for the total percentage of carcinoma. Unlike the Hi-MYC model, we did not observe invasive adenocarcinoma in any tissue sections and the highest grade lesion observed was carcinoma in situ (CIS) ( Figure 5D ) which is consistent with previous characterization of this GEMM (33) . In contrast with the Hi-MYC model, we observed no significant histological differences in animals treated with CX-5461 alone. This difference in response between these two models most likely stems from a lower dependence on MYC as a driver of tumorigenesis in the PTEN-deficient mouse and thus low levels of MYC do not sensitize these tumors to Pol I inhibition as a single agent. However, we observed a decreased incidence of carcinoma in situ (CIS) in animals treated with CX-6258 alone and a striking decrease in tumor burden after combination treatment ( Figure 5D ). Animals receiving the combination therapy had a ~50% decrease in incidence of CIS (P=0.03) ( Figure   5E ) and displayed HGPIN as their predominant pathology ( Figure 5D ). These observations are consistent with recent evidence that PIM kinases regulate PI3K signaling through indirect mTORC1 modulation (35) , which could decrease signalling downstream of AKT. Taken together these results in GEMM of advanced localised PC demonstrate strong pre-clinical efficacy of the benefit of targeting signaling to the ribosome at multiple fronts.
Patient derived xenografts from multi-drug resistant CRPC metastasis are sensitive to dual inhibition of Pol I and PIM kinases
The current challenge in the treatment of advanced PC is the progression to late stage disease, CRPC and the development of resistance to novel AR targeting agents (36) . Having demonstrated efficacy of our CX-5461/CX-6258 combination therapy in vitro and the Hi-MYC and PTEN-deficient in vivo models of PC, we tested the efficacy of this strategy using metastatic PC tissue obtained at autopsy. We used a patient derived xenograft (PDX) model in which thin slices of tissue are grafted under the renal capsule of immune deficient host mice. To take into account the heterogeneity of tissue during grafting, we devised a procedure ( Figure 6A ) whereby the tissue is sectioned and each contiguous slice is allocated to either a vehicle or drug treatment group. Considering, that this PDX approach requires that the whole experiment be done from the same starting graft due to tumor heterogeneity, it is not feasible to perform this experiment with more than two groups (e.g. vehicle vs. treatment). Using this approach we tested the combination of CX-5461 and CX-6258. Following engraftment, tumors were allowed to grow for 3 weeks followed by oral dosage over 9 days. Tumors were harvested and weighed ( Figure 6B ).
Comparison of graft weights from paired samples demonstrates a significant inhibition of tumor growth in the majority of drug treated samples. In 11 out of 16 pairs, the drug treated tumors had a lower weight than the corresponding vehicle treated tumor ( Figure 6C ) (P=0.04). Percentage of Ki-67 ( Figure 6D ) shows that these treated tumors have lower proliferation than vehicle treated pairs and increased cell death as marked by cleaved caspase-3 ( Figure 6E ). Considering that this tissue is derived from a metastasis isolated from a patient who failed to respond to conventional therapy and novel androgen targeted therapeutics, this significant result demonstrates the efficacy of this combination therapy in lethal PC.
Discussion
In this report, we describe the potential of RNA polymerase I transcription inhibition as a therapy for MYC-driven PC using a novel compound, CX-5461, in both human cells and GEMMs of PC that reflects the progression of human pathology. Pol I inhibition resulted in cell cycle arrest in human PC cell lines, even when p53 was mutated or lost, and this was associated with potent inhibition of colony formation in p53-null human lines and p53 wild type PC cells from the Hi-MYC mouse. These findings are consistent with our previous observation that the mutational status of p53 does not correlate with cell sensitivity to Pol I inhibition (26); however, it does significantly enhance inhibitor sensitivity (6) . This is an important finding as loss-of-function p53 mutations are among the most common in PC, being present in roughly 50% of cases (37).
Clegg et al. (28) previously described the resistance of Hi-MYC mice to rapamycin.
Additionally, Balakumaran et al. described that MYC-driven prostate cancer circumvents mTORC1 inhibition induced growth suppression because of incomplete or partial inhibition of mTORC1 (38) , which most likely sustains or enhances 4EBP1 activity. Additionally, PIM-1 can mediate resistance by upregulating receptor tyrosine kinase activity in response to PI3K pathway suppression (15) . Although it remains unclear whether PIM kinases also mediate this resistance to therapy in Hi-MYC mice, PIM-1 was shown to be among the most significantly upregulated oncogenes in PC (17) and we show that significant phosphorylation of 4E-BP1 is observed in our Hi-MYC tumor cell line, HM-5, which could be relieved with CX-6258 administration.
Interestingly, a recent study investigating MYC-driven colorectal tumorigenesis showed that targeting translation initiation bypasses this crosstalk signaling between MYC and mTOR resulting in reduced MYC levels in cancer (39).
Acute oral administration of CX-5461 and CX-6258 induced a 42% reduction in proliferative index in Hi-MYC adenocarcinoma and a remarkable decrease in the incidence of invasive tumor foci. It was recently described that PIM kinase inhibition had shown promising efficacy as a single agent in models of MYC-driven PC (30) . In contrast, the results of our study do not show significant efficacy in a MYC-driven autochthonous PC model. However, the cooperation between CX-6258 and CX-5461 is consistent with the data of Kirschner et al., showing that PIM kinase inhibition synergises well with agents that induce a p53 response in their mouse model of MYC-driven prostate cancer such as docetaxel and radiation therapy, standard therapies for recurrent PC (30) . PTEN-deficiency is a feature of approximately 40% of PC (37) , and here we show that this combination is also effective in a low MYC, PTEN deficiency-driven GEMM and PDX derived from human mCRPC. This is consistent with our hypothesis that this combination approach to targeting the ribosome will be efficacious in cancers featuring dysregulation of signalling via PI3K as well as MYC (40) . To our knowledge, we are the first group to demonstrate that targeting ribosome biogenesis and ribosome function simultaneously can be exploited therapeutically in clinically relevant models of PC.
21
The data presented here strongly supports the idea that MYC confers tumor sensitivity to Pol I inhibition alone and treatment efficacy is remarkably enhanced when combined with PIM inhibition. These findings are significant as they demonstrate that MYC and PIM oncogenes are profoundly co-operative in PC and drive cell addiction to ribosome transcription and mRNA translation. This work supports the potential treatment of human prostate cancer with novel therapeutic agents, especially those resistant to conventional therapy and are characterised by isolation from mice given longer term therapy with CX-5461 (50 mg/kg, bi-weekly, 9 doses, Scale bars = 100 µm) (n=3, mean ± SD, t-test *P=0.02). 
